A paradigm shift in the approach to identifying type 1 diabetes (T1D) is being advocated, as new research suggests that…
Read More
Sanofi’s Venglustat Receives Priority Review from US FDA for Type 3 Gaucher Disease
Sanofi has secured a significant milestone in its development of venglustat, an innovative oral glucosylceramide synthase inhibitor (GCSi), with the…
Read More
Expanding Screening for Type 1 Diabetes in Children Could Identify More Cases
A significant shift in the approach to identifying type 1 diabetes in children is being advocated for, with a new…
Read More
Groundbreaking Stem Cell Therapy Shows Promise in Reversing Type 1 Diabetes in Mice, Offering New Hope for Patients
Scientists from Stockholm, Sweden, affiliated with Karolinska Institutet and KTH Royal Institute of Technology, have reported a significant advancement in…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Novel Stem Cell Therapy Protocol Shows Significant Promise for Type 1 Diabetes Treatment, Reversing Disease in Mice.
Scientists at the forefront of regenerative medicine, based at the esteemed Karolinska Institutet and KTH Royal Institute of Technology in…
Read More
Novo Nordisk Launches Oral Ozempic in the US, Revolutionizing Type 2 Diabetes and Cardiovascular Risk Management
The landscape of type 2 diabetes management and cardiovascular risk reduction in the United States has been significantly reshaped with…
Read More
Sanofi Receives FDA Approval to Expand Tzield Use in Children as Young as One Year for Type 1 Diabetes Delay
Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read MoreYOU MAY HAVE MISSED
